Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04452084
Recruitment Status : Recruiting
First Posted : June 30, 2020
Last Update Posted : July 7, 2020
Singhealth Duke-NUS Oncology Academic Clinical Programme (ONCO ACP)
Singapore General Hospital
Information provided by (Responsible Party):
National Cancer Centre, Singapore

Brief Summary:

Recently, the evidence supports hippocampal avoidance with whole brain radiotherapy (HA-WBRT) as the recommended treatment option in patients with good prognosis and multiple brain metastases as it gives better neurocognitive preservation compared to historical whole brain radiotherapy controls. There is however often poor tumour control with this technique due to the low doses given. Stereotactic Radiosurgery (SRS), a form of focused radiotherapy which is given to patients who have a limited number of brain metastases, gives a higher radiation dose to the metastases resulting in better target lesion control. With improvements in radiation technology, advanced dose-painting techniques now allow a simultaneous integrate boost (SIB) dose to lesions whilst minimising doses to the hippocampus to potentially improve brain tumour control and preserve cognitive outcomes (HA-SIB-WBRT).

The Investigators believe that the SIB in HA-SIB-WBRT (experimental) will result in better functional and survival outcomes compared to HA-WBRT (control). Patients who are fit, have multiple brain metastases (5-25 lesions) and reasonable life expectancy (>6 months) will be recruited from NCCS over 2 years. Patients will be followed up the over the following year with imaging, toxicity data, quality of life, activities of daily living and cognitive measurements at set time points. The results will be compared across the 2 arms.

Patients with brain metastases are living longer. Maintaining functional independence and brain metastases control is thus increasingly important. Improved radiotherapy treatment techniques could provide better control and survival outcomes whilst maintain QoL and functional capacity.

Condition or disease Intervention/treatment Phase
Brain Metastases Radiation: HA-WBRT Radiation: HA-SIB-WBRT Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: Blinding is not feasible in this study and will not be performed.
Primary Purpose: Treatment
Official Title: Randomised Prospective Phase 2 Trial in Multiple Brain Metastases Comparing Outcomes Between Hippocampal Avoidance Whole Brain Radiotherapy With or Without Simultaneous Integrated Boost
Actual Study Start Date : June 15, 2020
Estimated Primary Completion Date : June 14, 2023
Estimated Study Completion Date : June 14, 2024

Arm Intervention/treatment
Active Comparator: Control Radiation: HA-WBRT
The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.

Experimental: Experimental Procedure Radiation: HA-SIB-WBRT
The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.

Primary Outcome Measures :
  1. Target lesion progression [ Time Frame: From time of randomisation to target lesion progression, up to 6 months after last day of radiotherapy. ]

Secondary Outcome Measures :
  1. Time to symptomatic brain metastases [ Time Frame: From time of randomisation to symptomatic brain progression, up to 12 months after last day of radiotherapy. ]
  2. Incidences of treatment-emergent adverse events (AE) [ Time Frame: From time of randomisation to 12 months after last day of radiotherapy. ]
    Identified and graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria.

  3. Overall Survival [ Time Frame: From time of randomisation to death from any cause, up to 12 months after last day of radiotherapy. ]
  4. Progression Free Survival [ Time Frame: From time of randomisation to overall progression, up to 12 months after last day of radiotherapy. ]
  5. Cognitive function [ Time Frame: From time of randomisation to 12 months after last day of radiotherapy. ]
    Assessed using Hopkins Verbal Learning Test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 21-80 years old patients with radiological confirmed brain metastases (5-25 lesions)
  • Histologically proven malignancy of primary cancer
  • ECOG performance status ≤ 2
  • Maximum lesion or cavity size ≤ 5cm

    • For patients with large (≥ 3cm) lesions, a neurosurgical consult is recommended as the risk of cerebral oedema and hydrocephalus is higher with RT. A Ventricular-peritoneal shunt/ surgical excision may be required prior to planning of RT
    • If brain surgery or other invasive procedures are performed, the treatment can only begin at least 2-weeks post-procedure
  • Life expectancy of at least 6 months
  • Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
  • Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatment
  • Not recommended or does not want Stereotactic Radiosurgery (SRS)
  • Agrees to be randomised to either HA-WBRT or HA-SIB-WBRT

Exclusion Criteria:

  • Prior whole brain radiotherapy

    o Prior SRS is not an exclusion. Details of treatment must be recorded.

  • Concurrent systemic cytotoxic treatment.

    o If patient is on systemic treatment a treatment break of at least 7 days for immunotherapy or chemotherapy and 3 days for targeted therapy is required before and after radiotherapy.

  • Leptomeningeal disease
  • Extensive extracranial disease, not controlled by systemic treatment
  • Severe, active co-morbidity, defined as follows:

    • Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy;
    • Unstable angina and/or uncontrolled congestive heart failure;
    • Myocardial infarction within the last 6 months;
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible.
    • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration;
    • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
    • Dementia, ongoing psychotic episodes or moderate-severe depression (PHQ-9).
    • Recent stroke in the past 3 months
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception;
  • ECOG performance status >2 despite a duration of high dose steroids
  • Symptomatic brain metastases limiting ADLs
  • Rapid brain progression
  • Patients unable to give informed consent
  • Total tumour planning target volume (PTV) >60cc
  • Radiological evidence of hydrocephalus
  • Contraindication to Gadolinium contrast-enhanced MRI brain
  • Patients who are unable to meet expected follow-up schedule (e.g. non-resident patients)
  • Patients with diagnoses of small cell carcinoma, lymphoma or primary brain tumour

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04452084

Layout table for location contacts
Contact: Brendan Chia, MB ChB BAO +65 6436 8000

Layout table for location information
National Cancer Center Singapore Recruiting
Singapore, Singapore, 169690
Sponsors and Collaborators
National Cancer Centre, Singapore
Singhealth Duke-NUS Oncology Academic Clinical Programme (ONCO ACP)
Singapore General Hospital
Layout table for investigator information
Principal Investigator: Brendan Chia, MB ChB BAO National Cancer Centre, Singapore
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Cancer Centre, Singapore Identifier: NCT04452084    
Other Study ID Numbers: HA-SIB-WBRT
First Posted: June 30, 2020    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Cancer Centre, Singapore:
Whole Brain Radiotherapy
Brain metastases
Cognitive outcomes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Brain Neoplasms
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases